Abstract CT251: Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct251
Abstract: Background Osi, an EGFR-TKI, is the preferred 1L treatment (tx) for EGFRm aNSCLC; however, resistance eventually develops in most pts. MET amplification is the most common known resistance mechanism to osi. Combining osi with savo,… read more here.
Keywords: osi savo; met amplified; progression; savo ... See more keywords